Holen Sie sich die Stockscreener-App
11.88
1.25%
-0.15
Handel nachbörslich:
11.88
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
How To Trade (STOK) - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 8.3%What's Next? - MarketBeat
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Lynx1 Capital Management LP's Strategic Acquisition in Stoke The - GuruFocus.com
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade - MSN
FY2024 EPS Forecast for Stoke Therapeutics Lifted by Analyst - Defense World
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Wedbush Lifts Earnings Estimates for Stoke Therapeutics - MarketBeat
Research Analysts Offer Predictions for STOK FY2024 Earnings - MarketBeat
Research Analysts Set Expectations for STOK FY2024 Earnings - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC - MarketBeat
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts - Simply Wall St
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues - Yahoo Finance
Stoke Therapeutics' (STOK) Buy Rating Reiterated at HC Wainwright - MarketBeat
Stoke Therapeutics Reports Q3 Results, Focuses on Phase 3 Study - TipRanks
Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.1%Time to Sell? - MarketBeat
Stoke Therapeutics earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics (STOK) Q3 2024 Earnings: Revenue Surges to $4 - GuruFocus.com
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - Business Wire
Vanguard Group Inc's Strategic Acquisition in Stoke Therapeutics Inc - GuruFocus.com
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Assenagon Asset Management S.A. Sells 155,723 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Skorpios Trust - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Lessened by SG Americas Securities LLC - MarketBeat
Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $20.83 - MarketBeat
Leerink Partnrs Analysts Lift Earnings Estimates for STOK - MarketBeat
Is Stoke Therapeutics Inc (STOK) worth investing in despite its overvalued state? - US Post News
Stoke Therapeutics (NASDAQ:STOK) Upgraded to "Strong-Buy" by Leerink Partnrs - MarketBeat
Stoke Therapeutics Inc (STOK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Shares Gap UpWhat's Next? - MarketBeat
Stoke Therapeutics Inc’s Market Journey: Closing Strong at 11.84, Up 3.86 - The Dwinnex
TD Cowen upgrades Stoke Therapeutics Inc (STOK) rating to an Outperform - Knox Daily
Leerink Partners Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Millennium Management LLC Has $3.91 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Renaissance Technologies LLC Has $151,000 Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday - MSN
Short Interest in Stoke Therapeutics, Inc. (NASDAQ:STOK) Declines By 19.9% - MarketBeat
Stoke Therapeutics assumed with an Outperform at Leerink - Yahoo Finance
Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases - Yahoo Finance
Stoke Therapeutics Inc (STOK)’s stock chart: A technical perspective - US Post News
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownWhat's Next? - MarketBeat
Recent Insider Activity Suggests Potential Gains for Stoke Therapeutics Inc (STOK) - Knox Daily
STOK’s Market Whiplash: 133.46% YTD Rise, -20.00% Plunge in 30 Days - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Trading 3.4% HigherWhat's Next? - MarketBeat
10 Small Cap Stocks with High Potential - Insider Monkey
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Healthcare of Ontario Pension Plan Trust Fund Buys 1,123,500 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Nothing is Better Than Stoke Therapeutics Inc (STOK) stock at the moment - SETE News
Stoke therapeutics executive sells $120k in stock - Investing.com
Stoke therapeutics executive sells $120k in stock By Investing.com - Investing.com UK
Stoke Therapeutics (NASDAQ:STOK) Shares Down 3.6% - MarketBeat
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):